Medicine for relieving autoimmune prostatitis and application thereof
Drugs prepared using live Lactobacillus johnsonii or its extracellular vesicles have solved the problems of immune tolerance and systemic side effects in the treatment of autoimmune prostatitis, achieving effective relief of prostatitis and improvement of pain sensation, restoring the intestinal barrier and targeting the delivery of biomolecules to block the inflammatory cascade.
CN122440679APending Publication Date: 2026-07-24南昌大学第一附属医院
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- CN202610647484.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-05-12
- Publication Date
- 2026-07-24
Smart Images
Figure CN122440679A_ABST
Abstract
The application relates to the field of biological medicine, and discloses a medicine for relieving autoimmune prostatitis and application thereof, which comprises an active ingredient and a pharmaceutically acceptable sterile phosphate buffer carrier; the active ingredient is live Lactobacillus johnsonii with a number of BNCC135265 or extracellular vesicles of Lactobacillus johnsonii; the final concentration of live bacteria in the medicine is 1x10 8 to 1x10 10 CFU / mL, which is used for preparing a preparation for intragastric administration; the extracellular vesicles contain 1x10 8 to 5x10 9 particles per unit dosage form, which is used for preparing a preparation for tail vein injection administration. By using the live bacteria with the specific number or the extracellular vesicles thereof, intestinal mucosa colonization can be achieved to block endotoxin into blood, or the extracellular vesicles can be enriched in prostate lesions to inhibit a nuclear factor-kappa B inflammatory signaling pathway, reduce synthesis of proinflammatory cytokines and lymphocyte infiltration, and finally realize relief of autoimmune prostatitis.
Need to check novelty before this filing date? Find Prior Art